1. Home
  2. ED vs VCEL Comparison

ED vs VCEL Comparison

Compare ED & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consolidated Edison Inc.

ED

Consolidated Edison Inc.

HOLD

Current Price

$100.15

Market Cap

34.6B

Sector

Utilities

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$40.75

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ED
VCEL
Founded
1884
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6B
2.0B
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
ED
VCEL
Price
$100.15
$40.75
Analyst Decision
Hold
Strong Buy
Analyst Count
13
5
Target Price
$104.54
$57.50
AVG Volume (30 Days)
1.8M
592.2K
Earning Date
02-19-2026
02-26-2026
Dividend Yield
3.42%
N/A
EPS Growth
7.94
236.54
EPS
5.74
0.25
Revenue
$16,593,000,000.00
$258,716,999.00
Revenue This Year
$11.45
$17.86
Revenue Next Year
$3.35
$18.55
P/E Ratio
$17.32
$163.62
Revenue Growth
10.39
14.05
52 Week Low
$87.28
$29.24
52 Week High
$114.87
$63.00

Technical Indicators

Market Signals
Indicator
ED
VCEL
Relative Strength Index (RSI) 55.55 65.33
Support Level $96.96 $35.33
Resistance Level $100.60 $38.15
Average True Range (ATR) 1.38 1.46
MACD 0.10 0.45
Stochastic Oscillator 71.23 88.69

Price Performance

Historical Comparison
ED
VCEL

About ED Consolidated Edison Inc.

Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: